Abstract：
OBJECTIVE: This study aimed to describe characteristics and treatment choices among AMABs (Assigned Male At Birth) and AFABs (Assigned Female At Birth) transgenders enrolled from March 2021 to July 2023 at the PTA S. Giorgio of the ASP3-Catania.
METHODS: A total of 145 patients were studied, and there was no prevalence of AMAB/AFAB. At first observation for AMABs, the age was 26 years and 25 years for AFABs, with 11 AMAB/AFAB declared as \"non-binary\" (average age 17 years).
RESULTS: In AMAB/AFAB, we evaluated hormonal treatment, efficacy, and dosage/hormonal levels. In AMABs, oral estradiol valerate (4 mg/day) or transdermal estradiol in gel (2 mg/day) + oral cyproterone acetate (25 mg/day) for both estrogenic formulations were used. Testosterone (TE), LH, FSH, and PRL at baseline and during chronic treatment were measured. In AFABs, we used injectable TE (250 mg/3-4 weeks or 1 g/12-16 weeks) or transdermal TE (60- 80 mg/day). In these patients, we analyzed blood count, LH, FSH, and TE. Hematocrit, hemoglobin, and red blood cell count showed a modest elevation after 4-6 months of treatment. About 32% of AFABs complained of transient uterine bleeding, but no hypertension or ovarian pathology was detected.
CONCLUSIONS: In AMABs, despite the short observation period, no patient showed an increased risk of myocardial infarction and ischemic stroke. Among AFABs, no increased risk of cardiovascular or cerebrovascular disease was observed. Furthermore, given the complexity of the phenomenon, the integration between the different professional figures who require specific and qualified skills is fundamental..
METHODS: A total of 145 patients were studied, and there was no prevalence of AMAB/AFAB. At first observation for AMABs, the age was 26 years and 25 years for AFABs, with 11 AMAB/AFAB declared as \"non-binary\" (average age 17 years).
RESULTS: In AMAB/AFAB, we evaluated hormonal treatment, efficacy, and dosage/hormonal levels. In AMABs, oral estradiol valerate (4 mg/day) or transdermal estradiol in gel (2 mg/day) + oral cyproterone acetate (25 mg/day) for both estrogenic formulations were used. Testosterone (TE), LH, FSH, and PRL at baseline and during chronic treatment were measured. In AFABs, we used injectable TE (250 mg/3-4 weeks or 1 g/12-16 weeks) or transdermal TE (60- 80 mg/day). In these patients, we analyzed blood count, LH, FSH, and TE. Hematocrit, hemoglobin, and red blood cell count showed a modest elevation after 4-6 months of treatment. About 32% of AFABs complained of transient uterine bleeding, but no hypertension or ovarian pathology was detected.
CONCLUSIONS: In AMABs, despite the short observation period, no patient showed an increased risk of myocardial infarction and ischemic stroke. Among AFABs, no increased risk of cardiovascular or cerebrovascular disease was observed. Furthermore, given the complexity of the phenomenon, the integration between the different professional figures who require specific and qualified skills is fundamental..
摘要：
目标：本研究旨在描述2021年3月至2023年7月在PTAS.Giorgio注册的AMAB（出生时分配男性）和AFAB（出生时分配女性）变性人的特征和治疗选择。ASP3-Catania。
方法：共研究了145例患者，并且没有AMAB/AFAB的患病率。在对AMAB的首次观察时，AFAB的年龄为26岁和25岁，11AMAB/AFAB被宣布为“非二进制”(平均年龄17岁)。
结果：在AMAB/AFAB中，我们评估了激素治疗，功效,和剂量/激素水平。在AMAB中，两种雌激素制剂均使用口服戊酸雌二醇(4mg/天)或经皮雌二醇凝胶(2mg/天)+口服醋酸环丙孕酮(25mg/天).睾酮(TE),LH,FSH,测量基线和慢性治疗期间的PRL。在AFAB中，我们使用了可注射TE(250mg/3-4周或1g/12-16周)或经皮TE(60-80mg/天).在这些患者中,我们分析了血细胞计数,LH,FSH,和TE。血细胞比容,血红蛋白,治疗4-6个月后，红细胞计数略有升高。约32%的AFAB主诉为短暂性子宫出血，但未检测到高血压或卵巢病理。
结论：在AMAB中，尽管观察期短,无患者显示心肌梗死和缺血性卒中风险增加.在AFAB中，未观察到心血管或脑血管疾病风险增加.此外，鉴于这种现象的复杂性，需要特定和合格技能的不同专业人物之间的整合是至关重要的。。
方法：共研究了145例患者，并且没有AMAB/AFAB的患病率。在对AMAB的首次观察时，AFAB的年龄为26岁和25岁，11AMAB/AFAB被宣布为“非二进制”(平均年龄17岁)。
结果：在AMAB/AFAB中，我们评估了激素治疗，功效,和剂量/激素水平。在AMAB中，两种雌激素制剂均使用口服戊酸雌二醇(4mg/天)或经皮雌二醇凝胶(2mg/天)+口服醋酸环丙孕酮(25mg/天).睾酮(TE),LH,FSH,测量基线和慢性治疗期间的PRL。在AFAB中，我们使用了可注射TE(250mg/3-4周或1g/12-16周)或经皮TE(60-80mg/天).在这些患者中,我们分析了血细胞计数,LH,FSH,和TE。血细胞比容,血红蛋白,治疗4-6个月后，红细胞计数略有升高。约32%的AFAB主诉为短暂性子宫出血，但未检测到高血压或卵巢病理。
结论：在AMAB中，尽管观察期短,无患者显示心肌梗死和缺血性卒中风险增加.在AFAB中，未观察到心血管或脑血管疾病风险增加.此外，鉴于这种现象的复杂性，需要特定和合格技能的不同专业人物之间的整合是至关重要的。。
